Group 1 - The company’s wholly-owned subsidiary, Yili Chuaning Investment Development Co., Ltd., plans to invest RMB 60 million in the Shanghai Lingang Qichuang Biotechnology Private Equity Fund, representing 7.50% of the total committed capital of RMB 800 million [1] - The fund's total committed capital has been reduced from RMB 800 million to RMB 565 million, increasing the company's stake from 7.50% to 10.62% [2] - The changes in the fund's structure are based on the current operational situation and are expected to help maintain stable operations of the fund [2] Group 2 - The fund has not yet completed the registration and filing process with the Asset Management Association of China, indicating some uncertainty in implementation [3] - The company will closely monitor the fund's progress and disclose updates in accordance with relevant regulations [3]

证券代码：301301 证券简称：川宁生物 公告编号：2025-004 伊犁川宁生物技术股份有限公司 关于全资子公司参与投资产业基金的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、投资产业基金的基本情况 伊犁川宁生物技术股份有限公司（以下简称"公司"）全资子公司伊犁生合 创域企业管理有限公司（以下简称"子公司"）（曾用名：伊犁川宁投资发展有 限公司）拟作为有限合伙人（LP）使用自有资金认缴出资人民币 6,000 万元参与 投资上海临港启创生科私募投资基金合伙企业（有限合伙）（曾用名：上海临港 大零号湾启创生科私募投资基金合伙企业（有限合伙））（以下简称"合伙企业"）， 合伙企业目标认缴出资总额为人民币 80,000 万元，公司将占合伙企业认缴出资 总额的 7.50%。具体内容详见公司于 2024 年 9 月 27 日在巨潮资讯网 （http://www.cninfo.com.cn）上发布的《关于全资子公司参与投资产业基金的公 告》（公告编号：2024-039）。 二、投资产业基金的变更情况 近日，公司收到合伙企业工商变更登记通知书，"上海临港大 ...

Investment Rating - The industry investment rating is "Overweight" [1] Core Insights - The prospects for biomanufacturing are broad, contributing to industrial upgrades. Biomanufacturing, centered on industrial biotechnology, utilizes enzymes and microbial cells in the processing of target products, including bio-based materials, chemicals, and bioenergy. Synthetic biology plays a crucial role as a platform technology in biomanufacturing. The global synthetic biology market is expected to maintain rapid growth, reaching nearly $50 billion by 2028 [3][4][22]. - Technological breakthroughs combined with policy support are driving the synthetic biology industry forward. Factors such as reduced costs of gene synthesis and sequencing, along with advancements in efficient gene editing technologies, provide a solid technical foundation for the rapid development of synthetic biology. Governments worldwide are increasingly prioritizing the development of synthetic biology, with various supportive policies being introduced [4][28]. - Synthetic biology is reshaping industrial models, offering more efficient and environmentally friendly synthesis solutions. It addresses issues associated with traditional chemical synthesis and natural extraction methods, such as high costs, limited yields, and environmental pollution. With breakthroughs in gene editing, enzyme engineering, and metabolic engineering, synthetic biology not only reduces drug production costs but also enhances capacity, enabling large-scale industrial production [4][5]. Summary by Sections Industry Overview - Biomanufacturing is defined as the processing of target products using industrial biotechnology, involving enzymes and microbial cells. Synthetic biology is a key platform technology in this field, enabling the design and construction of biological systems for various applications [13][14]. Policy Support and Technological Breakthroughs - The development of synthetic biology is supported by various policies and technological advancements. Governments are investing in funding, technology, and talent development to foster innovation and industrialization in this field [28][29]. - Major countries are establishing synthetic biology research centers and networks, with the UK and the US leading in policy initiatives to promote synthetic biology [29][30]. Synthetic Biology's Impact on Industrial Models - Synthetic biology is transforming production methods, achieving tasks that traditional biotechnologies cannot, while providing more efficient and eco-friendly synthesis options. This shift is crucial for addressing environmental challenges and enhancing production efficiency [4][5]. Investment Recommendations - Companies to watch include Chuan Ning Biological, Kingfisher Biotech, Kylin Biotech, and Huaxi Biological, which are positioned to benefit from the growth in synthetic biology [5].

Investment Rating - The industry investment rating is "Overweight" [1] Core Insights - The bio-manufacturing sector has vast potential and is poised to drive a new wave of industrial revolution, leveraging industrial biotechnology to produce bio-based materials, chemicals, and bioenergy [3][4] - The global synthetic biology market is expected to maintain rapid growth, projected to approach $50 billion by 2028, with a compound annual growth rate (CAGR) of approximately 24% from 2023 to 2028 [22][24] - Technological breakthroughs and policy support are driving the synthetic biology industry forward, with significant advancements in gene synthesis, sequencing, and editing technologies [4][37] Summary by Sections Industry Overview - Bio-manufacturing utilizes industrial biotechnology, enzymes, and microbial cells, playing a crucial role in producing bio-based materials and chemicals [13] - Synthetic biology is a design-driven science that re-engineers biological systems for useful purposes, with applications across various sectors including healthcare, agriculture, and chemicals [13][22] Policy Support and Technological Breakthroughs - Governments worldwide are increasingly prioritizing synthetic biology, with strategic plans and funding initiatives to support its development [28][29] - The reduction in costs for gene synthesis and sequencing technologies has laid a solid foundation for the rapid advancement of synthetic biology [37] Synthetic Biology Reshaping Industry Models - Synthetic biology is transforming production models, offering more efficient and environmentally friendly synthesis solutions compared to traditional methods [4][22] - The industry is expected to significantly reduce carbon emissions, with estimates suggesting a reduction of 1 to 2.5 billion tons of CO2 annually by 2030 through industrial biotechnology [4] Related Companies - Companies to watch include Chuan Ning Bio, Kingfisher Biotech, and Kailai Ying, which are positioned to benefit from advancements in synthetic biology [5] Investment Recommendations - The report suggests focusing on companies like Chuan Ning Bio, Kingfisher Biotech, and others that are leveraging synthetic biology for growth [5]

证券代码：301301 证券简称：川宁生物 公告编号：2025-003 伊犁川宁生物技术股份有限公司 二、公司在注册有效期内可分期发行超短期融资券，发行完成后，应通过交 易商协会认可的途径披露发行结果。 公司将根据银行间市场情况以及通知书的要求，严格按照《非金融企业债务 融资工具注册发行规则》《非金融企业债务融资工具注册工作规程》《非金融企 业债务融资工具信息披露规则》及有关规则指引规定，结合公司资金需求及市场 情况，在注册额度及有效期内择机发行超短期融资券，并及时履行信息披露义务。 特此公告。 伊犁川宁生物技术股份有限公司董事会 2025 年 2 月 7 日 伊犁川宁生物技术股份有限公司（简称"公司"）分别于 2024 年 4 月 22 日 召开的第二届董事会第五次会议及 2024 年 5 月 13 日召开的 2023 年年度股东大 会审议通过了《关于公司及所属子公司发行非金融企业债务融资工具的议案》， 同意公司及子（分）公司向中国银行间市场交易商协会（简称"交易商协会"） 申请注册发行总额不超过人民币 10 亿元（含）的银行间债券市场非金融企业债 务融资工具，发行品种包括超短期融资券、中期票据等相关监管部 ...

Financial Performance Forecast - The company expects a net profit attributable to shareholders of approximately 136,000 to 145,000 million yuan for 2024, representing a year-on-year increase of 44.59%[5] - The net profit after deducting non-recurring gains and losses is also projected to be between 136,000 and 145,000 million yuan, reflecting a growth of 45.31% compared to the previous year[5] - The performance forecast is based on preliminary calculations by the company's finance department and has not been audited by an accounting firm[11] - The performance forecast period is from January 1, 2024, to December 31, 2024[3] - The board of directors has provided a statement regarding the 2024 performance forecast[12] Factors Influencing Profit - The increase in profit is primarily driven by higher sales and prices of cephalosporin products in 2024[7] - The company has improved its production technology, effectively reducing production costs, which contributed to the increase in net profit[8] - The scale of interest-bearing liabilities has decreased, leading to a reduction in interest expenses compared to the previous year[10] Regulatory Compliance and Disclosure - The company will adhere to relevant laws and regulations for timely information disclosure, urging investors to make cautious decisions[11] - The company emphasizes that the specific financial data for 2024 will be disclosed in the official annual report[11]

四川省成都市高新区天府大道北段 966 号天府国际金融中心南塔 25 层-26 层 邮编：610041 25-26/F, South Tower of Tianfu International Finance Center, 966 North Tianfu Avenue, High-tech Zone, Chengdu, Sichuan 610041, P. R. China 电话/Tel : +86 28 6208 8001 传真/Fax : +86 28 6208 8111 www.zhonglun.com 北京中伦（成都）律师事务所 关于伊犁川宁生物技术股份有限公司 2025 年第一次临时股东大会的 法律意见书 致：伊犁川宁生物技术股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）及《上市公司股东大会规则》等法律、法 规及规范性文件的规定，北京中伦（成都）律师事务所（以下简称"本所"）指 派律师出席了伊犁川宁生物技术股份有限公司（以下简称"公司"）2025 年第一 次临时股东大会（以下简称"本次股东大会"），并对本次股东大会的相关 ...

二〇二四年十二月 | 第一章 | 总则 | 2 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 3 | | 第三章 | 股份 | 3 | | 第一节 | 股份发行 | 3 | | 第二节 | 股份增减和回购 | 4 | | 第三节 | 股份转让 | 6 | | 第四章 | 股东和股东大会 | 6 | | 第一节 | 股东 | 6 | | 第二节 | 股东大会的一般规定 | 8 | | 第三节 | 股东大会的召集 | 11 | | 第四节 | 股东大会的提案与通知 | 12 | | 第五节 | 股东大会的召开 | 14 | | 第六节 | 股东大会的表决和决议 | 17 | | 第五章 | 董事会 | 22 | | 第一节 | 董事 | 22 | | 第二节 | 董事会 | 25 | | 第六章 | 总经理及其他高级管理人员 | 33 | | 第七章 | 监事会 | 35 | | 第一节 | 监事 | 35 | | 第二节 | 监事会 | 35 | | 第八章 | 财务会计制度、利润分配和审计 | 37 | | 第一节 | 财务会计制度 | 37 | | 第二节 | 内部审计 | ...

证券代码：301301 证券简称：川宁生物 公告编号：2024-046 伊犁川宁生物技术股份有限公司 关于修订公司章程的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 伊犁川宁生物技术股份有限公司（以下简称"公司"）已于 2024 年 12 月 19 日召开第二届董事会第八次会议，审议通过了《关于修订公司章程的议案》，该 事项尚需提交公司 2025 年第一次临时股东大会审议。现将相关事项公告如下： 一、公司章程修订情况 根据《中华人民共和国公司法》《中华人民共和国证券法》及《上市公司章 程指引（2023 年修订）》等法律、法规及规范性文件，结合公司实际情况，对现 行《伊犁川宁生物技术股份有限公司章程》（以下简称"《公司章程》"）中的有关 条款进行相应修订，同时提请股东大会授权公司经营管理层在股东大会审议通过 后，依据相关规定办理变更登记手续。 本次拟对《公司章程》具体修订内容如下： 特此公告。 伊犁川宁生物技术股份有限公司董事会 | 原条款 | 修订后条款 | | --- | --- | | 第二十六条 公司因本章程第二十四 | 第二十六条 公司因本章程 ...

长江证券承销保荐有限公司 关于伊犁川宁生物技术股份有限公司 2025 年度日常关联交易预计的核查意见 长江证券承销保荐有限公司（以下简称"长江保荐"或"保荐机构"）作为 伊犁川宁生物技术股份有限公司（以下简称"川宁生物"或"公司"）首次公开 发行股票并在创业板上市持续督导保荐机构，根据《证券发行上市保荐业务管理 办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所创业板上市公司 自律监管指引第 2 号——创业板上市公司规范运作》及《深圳证券交易所上市公 司自律监管指引第 13 号——保荐业务》等有关规定，对公司 2025 年度日常关联 交易预计进行了审慎核查，具体情况如下： 一、日常关联交易基本情况 （一）日常关联交易概述 为满足公司日常生产经营的正常需要，确保公司供销渠道的稳定性，根据公 司2024年度日常关联交易的实际情况，结合公司业务发展需要，预计公司及子公 司拟与关联方四川科伦药业股份有限公司（以下简称"科伦药业"）及其下属子 公司（以下统称"科伦药业集团"）发生的采购及销售商品、接受及提供劳务； 与关联方伊犁恒辉淀粉有限公司（以下简称"恒辉淀粉"）发生的委托加工原材 料和材料采购；与关联方伊犁 ...